Chemical. (G) Monoester of 2-propenoic acid, 2-hydroxyethyl ester and aliphatic isocyanate.

Use/Production. (S) Coating for electronics industry. Prod. range: Confidential.

Toxicity Data. Acute oral toxicity: LD50 > 5 g/kg species (rat). Acute dermal toxicity: LD50 > 2 g/kg species (rabbit). Eye irritation: none species (rabbit). Skin irritation: moderate species (rabbit).

P 91-1297

Manufacturer. Donlar Corporation.

Chemical. (S) Potassium salt of polyaspartic acid.

Use/Production. (S) Anti-redeposition agent in detergent. Prod. range: Confidential.

Toxicity Data. Acute oral toxicity: LD50 > 5 g/kg species (rat).

P 91-1298

Manufacturer. Donlar Corporation.

Chemical. (S) Ammonium salt of polyaspartic acid.

Use/Production. (S) Anti-redeposition agent in detergent. Prod. range: Confidential.

Toxicity Data. Acute oral toxicity: LD50 > 5 g/kg species (rat).

P 91-1299

Manufacturer. Donlar Corporation.

Chemical. (S) Polyaspartic acid.

Use/Production. (S) Anti-redeposition agent in detergent. Prod. range: Confidential.

Toxicity Data. Acute oral toxicity: LD50 > 5 g/kg species (rat).

Dated: August 16, 1991.

Steven Newburg-Rinn,

Acting Director, Information Management Division, Office of Toxic Substances.

[FR Doc. 91-20046, Filed 8-20-91; 8:45am]

BILLING CODE 6560-50-F

[OPTS-59301; FRL 3942-5]

Toxic and Hazardous Substances; Test Market Exemption Applications

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: EPA may upon application exempt any person from the premanufacturing notification requirements of section 5(a) or (b) of the Toxic Substance Control Act (TSCA) to permit the person to manufacture or process a chemical for test marketing purposes under section 5(h)(1) of TSCA. Requirements for test marketing exemption (TME) applications, which must either be approved or denied within 45 days of receipt are discussed in EPA's final rule published in the **Federal Register** of May 13, 1983 (48 FR 21722). This notice, issued under section 5(h)(6) of TSCA, announces receipt of 2 applications for exemption, provides a summary, and requests comments on the appropriateness of granting these exemptions.

DATES: *Written comments by:*

T 91-24, 91-25, September 4, 1991.

ADDRESSES: Written comments, identified by the document control number "(OPTS-59301)" and the specific TME number should be sent to: Document Processing Center (TS-790), Office of Toxic Substances, Environmental Protection Agency, 401 M St., SW., rm. L-100, Washington, DC 20460, (202) 382-3532.

FOR FURTHER INFORMATION CONTACT: David Kling, Acting Director, Environmental Assistance Division (TS-799), Office of Toxic Substances, Environmental Protection Agency, rm. EB-44, 401 M St., SW., Washington, DC 20460, (202) 554-1404, TDD (202) 554-0551.

SUPPLEMENTARY INFORMATION: The following notice contains information extracted from the nonconfidential version of the submission provided by the manufacturer of the TME received by EPA. The complete nonconfidential document is available in the TSCA Public Docket Office NE-G004 at the above address between 8 a.m. and noon and 1 p.m. and 4 p.m., Monday through Friday, excluding legal holidays.

T 91-24

Close of Review Period. September 18, 1991.

Importer. Confidential.

Chemical. (G) Polyisobutylene amine (PIBA).

Use/Import. (G) Gasoline additive. Import range: Confidential.

T 91-25

Close of Review Period. September 18, 1991.

Manufacturer. Confidential.

Chemical. (G) Cationic aqueous polyurethane dispersion.

Use/Production. (S) Leather treatment. Prod. range: 15,000-64,000 kg/yr.

Dated: August 15, 1991.

Steven Newburg-Rinn,

Acting Director, Information Management Division, Office of Toxic Substances.

[FR Doc. 91-20048 Filed 8-20-91 8:45 am]

BILLING CODE 6560-50-F

[OPTS-59912; FRL 3942-4]

Toxic and Hazardous Substances; Certain Chemicals Premanufacture Notices

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: Section 5(a)(1) of the Toxic Substances Control Act (TSCA) requires any person who intends to manufacture or import a new chemical substance to submit a premanufacture notice (PMN) to EPA at least 90 days before manufacture or import commences. Statutory requirements for section 5(a)(1) premanufacture notices are discussed in the final rule published in the **Federal Register** of May 13, 1983 (48 FR 21722). In the **Federal Register** of November 11, 1984, (49 FR 46066) (40 CFR 723.250), EPA published a rule which granted a limited exemption from certain PMN requirements for certain types of polymers. Notices for such polymers are reviewed by EPA within 21 days of receipt. This notice announces receipt of 12 such PMN(s) and provides a summary of each.

DATES: Close of review periods:

Y 91-145, June 1, 1991.

Y 91-188, August 19, 1991.

Y 91-189, 91-190, August 20, 1991.

Y 91-192, 91-193, 91-194, 91-195, 91-196, 91-197, 91-198, August 21, 1991.

Y 91-199, August 27, 1991.

FOR FURTHER INFORMATION CONTACT: David Kling, Acting Director, Environmental Assistance Division (TS-799), Office of Toxic Substances, Environmental Protection Agency, rm. E-545, 401 M St., SW., Washington, DC 20460, (202) 554-1404, TDD (202) 554-0551.

SUPPLEMENTARY INFORMATION: The following notice contains information extracted from the nonconfidential version of the submission provided by the manufacturer on the PMNs received by EPA. The complete nonconfidential document is available in the TSCA Public Docket Office, NE-G004 at the above address between 8 a.m. and noon and 1 p.m. and 4 p.m., Monday through Friday, excluding legal holidays.

Y 91-145

Manufacturer. Confidential.

Chemical. (G) Hydroxy functional acrylic polymer.

Use/Production. (S) Coatings. Prod. range: Confidential.

Y 91-188

Importer. Confidential.

Chemical. (G) Aliphatic-aromatic polyurethane.
Use/Import. (G) Industrial adhesive. Import range: Confidential.

Y 91-189

Importer. Confidential.
Chemical. (G) Styrenated acrylic copolymer.
Use/Import. (G) Paint. Import range: Confidential.

Y 91-190

Importer. Confidential.
Chemical. (G) Styrenated acrylic copolymer.
Use/Import. (G) Paint. Import range: Confidential.

Y 91-192

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-193

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-194

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-195

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-196

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-197

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-198

Importer. S. C. Johnson & Son, Inc.
Chemical. (G) Aqueous acrylic polymer.
Use/Import. (G) Open, nondispersive use. Import range: Confidential.

Y 91-199

Manufacturer. PPG Industries, Inc.
Chemical. (G) Silicones and silicones, dimethyl, methyl alkyl.
Use/Production. (G) Siloxanes and silicone, dimethyl methyl alkyl. Prod. range: Confidential.

Dated: August 15, 1991.

Steven Newburg-Rinn,

Acting Director, Information Management Division, Office of Toxic Substances.

[FR Doc. 91-20049 Filed 8-20-91; 8:45 am]
BILLING CODE 6560-50-F

FEDERAL MARITIME COMMISSION

Thompson Shipping Co., Ltd., et al.; Agreement(s) Filed

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street NW., room 10325. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the Federal Register in which this notice appears. The requirements for comments are found in 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 217-011343.

Title: Thompson Shipping Co. Ltd./ Cayman Islands Shipping Ltd. Space Charter Agreement.

Parties:

Thompson Shipping Co. Ltd.,
Cayman Islands Shipping Ltd.

Synopsis: The proposed Agreement would permit Cayman Islands Shipping Ltd. to charter space from Thompson Shipping Co. Ltd. in the trade from Tampa, Flordia to Cayman Islands, B.W.I.

Dated: August 15, 1991.

By Order of the Federal Maritime Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 91-19951 Filed 8-20-91; 8:45 am]
BILLING CODE 6730-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 88N-0394]

Generic Animal Drug and Patent Term Restoration Act; Eighth Policy Letter; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of an eighth policy letter, dated July 23, 1991, concerning implementation of the Generic Animal Drug and Patent Term Restoration Act (GADPTRA). The letter states the Center for Veterinary Medicine's (CVM'S) policy on generic copying of certain pre-1962 drug products which were reviewed for effectiveness under the National Academy of Sciences/ National Research Council, Drug Efficacy Study Implementation (NAS/ NRC DESI) program. The agency is soliciting comments on the letter.

DATES: Written comments may be submitted at any time regarding this or previous policy letters or implementation of GADPTRA in general.

ADDRESSES: Submit written requests for single copies of the eighth policy letter to the Industry Information Staff (HFV-12), Center for Veterinary Medicine, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send two self-addressed adhesive labels to assist that office in processing your request. Submit written comments on the letter to the Dockets Management Branch (HFA-305), Food and Drug Administration, Park Bldg., rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with docket number found in brackets in the heading of this document. The policy letter and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8623.

SUPPLEMENTARY INFORMATION: On November 16, 1988, the President signed

GADPTRA into law (Pub. L. 100–670, 102 Stat. 3971). GADPTRA amends the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 301 *et seq.*) by extending the generic approval system to copies of new animal drugs that were approved after October 10, 1962, and provides patent extension of certain animal drugs.

FDA has published notices of availability for seven policy letters concerning implementation of GADPTRA. See the **Federal Register** of June 18, 1990 (55 FR 24645) for a list of the publication dates and topics of the first five letters. In the **Federal Register** of October 31, 1990 (55 FR 45860), FDA published a notice of availability of the sixth letter dated October 17, 1990. In the **Federal Register** of April 15, 1991 (56 FR 15083), FDA published a notice of availability of the seventh policy letter dated March 20, 1991.

FDA is now announcing the availability of an eighth policy letter dated July 23, 1991. The letter announces that CVM will not permit generic copying of certain new animal drugs that were: (1) Approved before October 10, 1962, (2) reviewed under the NAS/NRC DESI program, (3) found to be less than effective, and (4) not supported by supplemental new animal drug applications to bring the drugs into full compliance with the DESI requirements (i.e., "DESI-finalize"). The letter also discusses how and why CVM is removing the nonfinalized drugs from the list of drugs that have been approved for safety and effectiveness in the publication entitled FDA Approved Animal Drug Products (the Green Book).

The agency anticipates that changes in these policy statements may occur in the future. When and if changes are made, copies of the revised policy statements will be placed on display in the Dockets Management Branch (address above) and a notice of availability will be published in the **Federal Register.**

In addition, the subjects contained in these policy statements may be addressed in the regulations that will implement GADPTRA. Comments submitted in response to this notice will be considered in the drafting of the proposed regulations.

Dated: August 15, 1991.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 91–20052 Filed 8–20–91; 8:45 am]

BILLING CODE 4160–01–M

Health Resources and Services Administration

Project Grants for Renovation or Construction at Tertiary Perinatal Facilities in Those States Whose Infant Mortality Rate Is Significantly Above the National Average

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of availability of funds.

SUMMARY: The Bureau of Health Resources Development (BHRD), Health Resources and Services Administration (HRSA), announces that fiscal year (FY) 1991 funds are available for project grants for renovation or construction at tertiary perinatal facilities in those states whose infant mortality rate is significantly above the national average. Funds were appropriated for this purpose by Public Law 101–517 under the authority of section 1610(b) of the Public Health Service (PHS) Act.

DATES: To receive consideration, applications must be received by the close of business October 21, 1991, by the Grants Management Officer, Ms. Glenna Wilcom, at the address below. Applications will meet the deadline if they are either: (1) Received on or before the deadline date; or (2) postmarked on or before the deadline date, and received in time for submission to the review committee. A legibly dated receipt from a commercial carrier or U.S. Postal Service will be accepted instead of a postmark. Private metered postmarks will not be acceptable as proof of timely mailing. Hand delivered applications must be received by 5 p.m. October 21, 1991. Grant applications that are received after the deadline date will be returned to the applicant.

FOR FURTHER INFORMATION CONTACT: Additional information relating to technical and program issues may be obtained from Ms. Katharine Buckner, Division of Facilities Assistance and Recovery, Bureau of Health Resources Development, Parklawn Building, room 11A–10, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443–0271. Grant applications and additional information regarding business, administrative or fiscal issues related to the awarding of grants under this Notice may be requested from the Grants Management Officer, Ms. Glenna Wilcom, Parklawn Building, room 13A–38, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443–2280. Applicants for grants will use Form PHS 5161–1, approved under OMB Control Number 0937–0189.

SUPPLEMENTARY INFORMATION:

Program Background and Objectives

Public Law 101–517 provides funds for grants under the authority of section 1610(b) of the PHS Act, for renovation or construction at tertiary perinatal facilities in those states whose infant mortality rate is significantly above the national average. The amount of any grant may not exceed 80 percent of the cost of the project for which the grant is made unless the project is located in an area determined by the Secretary to be an urban or rural poverty area, in which case the grant may cover up to 100 percent of such costs. (Urban or rural poverty area is defined as a medically underserved area designated by the Secretary (42 CFR 51c.102)). For information regarding the current medically underserved areas, contact the Director, Office of Shortage Designation, room 4–101, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, or telephone (301) 443–6932.

The purpose of these funds is to support the construction and/or renovation of facilities at institutions with existing tertiary perinatal programs.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS led national activity for setting priority areas. This program announcement is specifically related to the Maternal and Infant Health Objectives of Healthy People 2000. Potential applicants may obtain a copy of Healthy People 2000 (Full Report; Stock No. 017–001–00474–0) or Healthy People 2000 (Summary Report; Stock No. 017–001–00473–1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325 (telephone 202–783–3238).

Availability of Funds

A total of $966,000 is available in FY 1991 to be awarded for renovation or construction at tertiary perinatal facilities in those states whose infant mortality rate is significantly above the national average. It is anticipated that up to two grants averaging approximately $483,000 each will be awarded.

Eligible Applicants

To be eligible, an applicant must: (1) Be a public or private nonprofit entity; (2) have a source of funding to meet the non-Federal portion of the eligible construction cost; (3) have title to a